EP1720559A4 - An anti-inflammatory, cytoprotective factor derivable from a probiotic organism - Google Patents

An anti-inflammatory, cytoprotective factor derivable from a probiotic organism

Info

Publication number
EP1720559A4
EP1720559A4 EP05722783A EP05722783A EP1720559A4 EP 1720559 A4 EP1720559 A4 EP 1720559A4 EP 05722783 A EP05722783 A EP 05722783A EP 05722783 A EP05722783 A EP 05722783A EP 1720559 A4 EP1720559 A4 EP 1720559A4
Authority
EP
European Patent Office
Prior art keywords
inflammatory
probiotic organism
derivable
cytoprotective factor
cytoprotective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05722783A
Other languages
German (de)
French (fr)
Other versions
EP1720559A1 (en
Inventor
Eugene B Chang
Elaine O Petrof
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of EP1720559A1 publication Critical patent/EP1720559A1/en
Publication of EP1720559A4 publication Critical patent/EP1720559A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
EP05722783A 2004-02-06 2005-02-04 An anti-inflammatory, cytoprotective factor derivable from a probiotic organism Withdrawn EP1720559A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54272504P 2004-02-06 2004-02-06
US56399604P 2004-04-20 2004-04-20
PCT/US2005/003765 WO2005077389A1 (en) 2004-02-06 2005-02-04 An anti-inflammatory, cytoprotective factor derivable from a probiotic organism

Publications (2)

Publication Number Publication Date
EP1720559A1 EP1720559A1 (en) 2006-11-15
EP1720559A4 true EP1720559A4 (en) 2009-07-22

Family

ID=34864503

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05722783A Withdrawn EP1720559A4 (en) 2004-02-06 2005-02-04 An anti-inflammatory, cytoprotective factor derivable from a probiotic organism

Country Status (4)

Country Link
EP (1) EP1720559A4 (en)
AU (1) AU2005212311A1 (en)
CA (1) CA2558618A1 (en)
WO (1) WO2005077389A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2912916B1 (en) * 2007-02-26 2009-05-22 Oreal COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A CELL CULTURE MEDIUM
FR2912917B1 (en) 2007-02-26 2012-05-18 Oreal CONDITIONED MEDIUM AND USES THEREOF
US20130209411A1 (en) * 2010-02-11 2013-08-15 Technische Universitat Munchen Lactocepins For Use in the Treatment of IP-10-Mediated Inflammatory Diseases
CN116115582B (en) * 2022-11-10 2024-04-16 重庆大学 Engineering probiotics packaged by prodrug as well as preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025533A1 (en) * 1994-03-18 1995-09-28 The President And Fellows Of Harvard College PROTEASOME REGULATION OF NF-λB ACTIVITY
WO1999022729A1 (en) * 1997-10-31 1999-05-14 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096711A (en) * 1998-02-25 2000-08-01 Sherman; Michael Hsp72 induction and applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995025533A1 (en) * 1994-03-18 1995-09-28 The President And Fellows Of Harvard College PROTEASOME REGULATION OF NF-λB ACTIVITY
WO1999022729A1 (en) * 1997-10-31 1999-05-14 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BREMNER P ET AL: "NATURAL PRODUCTS AS TARGETED MODULATORS OF THE NUCLEAR FACTOR-KAPPAB PATHWAY", JOURNAL OF PHARMACY AND PHARMACOLOGY, PHARMACEUTICAL PRESS, vol. 54, no. 4, 1 April 2002 (2002-04-01), pages 453 - 472, XP008004075, ISSN: 0022-3573 *
CONNER E M ET AL: "Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 282, no. 3, 1 September 1997 (1997-09-01), pages 1615 - 1622, XP002093378, ISSN: 0022-3565 *
GIONCHETTI P., RIZZELLO F.: "CBP-1011 InKine Pharmaceutical Co.", IDRUGS, vol. 4, no. 8, 2001, pages 935 - 938, XP002531026, Retrieved from the Internet <URL:http://www.biomedcentral.com/content/pdf/cd-417730.pdf> [retrieved on 20090605] *
KOJIMA KEISHI ET AL: "Enteric flora and lymphocyte-derived cytokines determine expression of heat shock proteins in mouse colonic epithelial cells.", GASTROENTEROLOGY, vol. 124, no. 5, May 2003 (2003-05-01), pages 1395 - 1407, XP002531020, ISSN: 0016-5085 *
MENARD S ET AL: "Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport", GUT, BRITISH MEDICAL ASSOCIATION, LONDON, UK, vol. 53, no. 6, 1 June 2004 (2004-06-01), pages 821 - 828, XP002327491, ISSN: 0017-5749 *
ODASHIMA MASARU ET AL: "Induction of a 72-kDa heat-shock protein in cultured rat gastric mucosal cells and rat gastric mucosa by zinc L-carnosine.", DIGESTIVE DISEASES AND SCIENCES, vol. 47, no. 12, December 2002 (2002-12-01), pages 2799 - 2804, XP002531022, ISSN: 0163-2116 *
PAJONK FRANK ET AL: "N-acetyl-L-cysteine inhibits 26s proteasome function: Implications for effects on NF-kappaB activation", FREE RADICAL BIOLOGY AND MEDICINE, vol. 32, no. 6, 15 March 2002 (2002-03-15), pages 536 - 543, XP002531024, ISSN: 0891-5849 *
PESSI TANJA ET AL: "Antiproliferative effects of homogenates derived from five strains of candidate probiotic bacteria", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 65, no. 11, November 1999 (1999-11-01), pages 4725 - 4728, XP002531025, ISSN: 0099-2240 *
PETROF E O ET AL: "Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 127, no. 5, 1 November 2004 (2004-11-01), pages 1474 - 1487, XP002350294, ISSN: 0016-5085 *
PRITTS TIMOTHY A ET AL: "Proteasome inhibitors induce heat shock response and increase IL-6 expression in human intestinal epithelial cells", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 282, no. 4 Part 2, April 2002 (2002-04-01), pages R1016 - R1026, XP002531019, ISSN: 0002-9513 *
RACHMILEWITZ ET AL: "Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 126, no. 2, 1 February 2004 (2004-02-01), pages 520 - 528, XP005314207, ISSN: 0016-5085 *
SCHULTZ MICHAEL ET AL: "Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases", DIGESTIVE DISEASES, KARGER, BASEL, CH, vol. 21, no. 2, 1 January 2003 (2003-01-01), pages 105 - 128, XP009112597, ISSN: 0257-2753 *
See also references of WO2005077389A1 *
URAYAMA SHIRO ET AL: "Dexamethasone protection of rat intestinal epithelial cells against oxidant injury is mediated by induction of heat shock protein 72", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 10, 15 November 1998 (1998-11-15), pages 1860 - 1865, XP002531023, ISSN: 0021-9738 *
VOLLOCH V ET AL: "A NATURAL EXTRACELLULAR FACTOR THAT INDUCES HSP72, INHIBITS APOPTOSIS, AND RESTORES STRESS RESISTANCE IN AGED HUMAN CELLS ù", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 253, 1 January 1999 (1999-01-01), pages 483 - 492, XP002907082, ISSN: 0014-4827 *
WANG X ET AL: "SUPPRESSION OF NF-KAPPAB-DEPENDENT PROINFLAMMATORY GENE EXPRESSION IN HUMAN RPE CELLS BY A PROTEASOME INHIBITOR", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, ASSOCIATION FOR RESEARCH IN VISION AND OPHTHALMOLOGY, US, vol. 40, no. 2, 1 February 1999 (1999-02-01), pages 477 - 486, XP001106154, ISSN: 0146-0404 *
YIN LEI ET AL: "Butyrate suppression of colonocyte NF-kappaB activation and cellular proteasome activity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 44641 - 44646, XP002531021, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP1720559A1 (en) 2006-11-15
CA2558618A1 (en) 2005-08-25
WO2005077389A1 (en) 2005-08-25
AU2005212311A1 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
IL181588A0 (en) PRODUCTION OF-TNFR-Ig
TWI349097B (en) A projectile
ZA200705507B (en) High conversion hydroprocessing
GB0513654D0 (en) Variable displacement turbine liner
AP2239A (en) Direct currency conversion.
GB0709996D0 (en) A jet-printing assembly
EP1720559A4 (en) An anti-inflammatory, cytoprotective factor derivable from a probiotic organism
HK1078413A2 (en) A brassiere
HK1086224A1 (en) Spiral die assembly
GB0407897D0 (en) A unison ring
EP1889636A4 (en) V. a. pervak antireflexive endotracheal tube
GB0418203D0 (en) A tracking assembly
ZA200609183B (en) Capsules derived from asymmetrical production
GB0422478D0 (en) A flow arrangement
GB2417212B (en) A projectile
GB0406956D0 (en) A pipe forming assembly
HK1069714A2 (en) Windmill.
GB0417838D0 (en) The Edwards military-kit carrier
SG121914A1 (en) A connecting arrangement
HK1074730A2 (en) Nano energy cup.
GB0407854D0 (en) C.L.A.D.turbine
GB2412652B (en) A connection assembly
GB0409990D0 (en) F.a.h.
GB0406270D0 (en) A balloon
ZA200508173B (en) A tamper-indicating container assembly

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060906

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090623

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090922